476 related articles for article (PubMed ID: 29678177)
1. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis.
Amand C; Tong S; Kieffer A; Kyaw MH
BMC Health Serv Res; 2018 Apr; 18(1):294. PubMed ID: 29678177
[TBL] [Abstract][Full Text] [Related]
2. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases.
Paramore LC; Ciuryla V; Ciesla G; Liu L
Pharmacoeconomics; 2004; 22(5):275-84. PubMed ID: 15061677
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
[TBL] [Abstract][Full Text] [Related]
4. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
[TBL] [Abstract][Full Text] [Related]
5. Long-term Assessment of Healthcare Utilization 5 Years After Respiratory Syncytial Virus Infection in US Infants.
Simões EAF; Chirikov V; Botteman M; Kwon Y; Kuznik A
J Infect Dis; 2020 Mar; 221(8):1256-1270. PubMed ID: 31165865
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants.
Ledbetter J; Brannman L; Wade SW; Gonzales T; Kong AM
J Med Econ; 2020 Feb; 23(2):139-147. PubMed ID: 31432723
[No Abstract] [Full Text] [Related]
7. Economic-Burden Trajectories in Commercially Insured US Infants With Respiratory Syncytial Virus Infection.
Chirikov VV; Simões EAF; Kuznik A; Kwon Y; Botteman M
J Infect Dis; 2020 Mar; 221(8):1244-1255. PubMed ID: 30982895
[TBL] [Abstract][Full Text] [Related]
8. Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study.
Thampi N; Knight BD; Thavorn K; Webster RJ; Lanctot K; Hawken S; McNally JD
CMAJ Open; 2021; 9(4):E948-E956. PubMed ID: 34667075
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
11. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants.
Palmer L; Hall CB; Katkin JP; Shi N; Masaquel AS; McLaurin KK; Mahadevia PJ
Pediatr Pulmonol; 2010 Aug; 45(8):772-81. PubMed ID: 20632403
[TBL] [Abstract][Full Text] [Related]
12. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.
Bhuiyan MU; Luby SP; Alamgir NI; Homaira N; Sturm-Ramirez K; Gurley ES; Abedin J; Zaman RU; Alamgir A; Rahman M; Ortega-Sanchez IR; Azziz-Baumgartner E
J Glob Health; 2017 Jun; 7(1):010412. PubMed ID: 28702175
[TBL] [Abstract][Full Text] [Related]
13. Incidence of respiratory syncytial virus related health care utilization in the United States.
Tong S; Amand C; Kieffer A; Kyaw MH
J Glob Health; 2020 Dec; 10(2):020422. PubMed ID: 33110581
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
15. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants.
Shi N; Palmer L; Chu BC; Katkin JP; Hall CB; Masaquel AS; Mahadevia PJ
J Med Econ; 2011; 14(3):335-40. PubMed ID: 21524154
[TBL] [Abstract][Full Text] [Related]
16. Estimates of hospitalization attributable to influenza and RSV in the US during 1997-2009, by age and risk status.
Matias G; Taylor R; Haguinet F; Schuck-Paim C; Lustig R; Shinde V
BMC Public Health; 2017 Mar; 17(1):271. PubMed ID: 28320361
[TBL] [Abstract][Full Text] [Related]
17. A comparison of healthcare resource use for rotavirus and RSV between vulnerable children with co-morbidities and healthy children: a case control study.
Pockett RD; Campbell D; Carroll S; Rajoriya F; Adlard N
J Med Econ; 2013; 16(4):560-5. PubMed ID: 23391124
[TBL] [Abstract][Full Text] [Related]
18. Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases.
Fuldeore M; Yang H; Du EX; Soliman AM; Wu EQ; Winkel C
Fertil Steril; 2015 Jan; 103(1):163-71. PubMed ID: 25455535
[TBL] [Abstract][Full Text] [Related]
19. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk.
Rietveld E; De Jonge HC; Polder JJ; Vergouwe Y; Veeze HJ; Moll HA; Steyerberg EW
Pediatr Infect Dis J; 2004 Jun; 23(6):523-9. PubMed ID: 15194833
[TBL] [Abstract][Full Text] [Related]
20. A Real-World Analysis of Patient Characteristics and Predictors of Hospitalization Among US Medicare Beneficiaries with Respiratory Syncytial Virus Infection.
Wyffels V; Kariburyo F; Gavart S; Fleischhackl R; Yuce H
Adv Ther; 2020 Mar; 37(3):1203-1217. PubMed ID: 32026380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
